Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Business https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Inovio shares fall 33% after waiting for COVID-19 vaccine trial

Inovio shares fall 33% after waiting for COVID-19 vaccine trial



Shares of Inovio Pharmaceuticals Inc. INO,
+ 10.21%
were suspended and then fell 33.6% when they resumed market trading on Monday, when the company said the Phase 2/3 clinical trial for its COVID-19 applicant was in “partial clinical detention” while answering additional questions. from Food and Drug Administration. The detention was not due to an adverse event that paused the Phase 3 study for AstraZeneca AZN,
+ 2.47%

AZN,
+ 0.1

8%
and the experimental coronavirus vaccine at Oxford University. Inovio said in a news release that it is working on answers to the regulator’s questions, plans to respond to the FDA in October, and then the agency has 30 days to issue a decision on whether the process can move forward. The Phase 1 process is still ongoing. Inovio shares have risen 413.3% so far this year, while the S&P 500 SPX,
+ 1.59%
is 21% more.


Source link